Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201/Xeomin for glabellar frown lines
2005-004416-78Phase 3Completed
- Sponsor
- Merz
- Start
- Jul 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in glabellar furrowing (3 arms), sponsored by Merz. Primary endpoints: Responder rate at maximum frown at Day 30 by investigator Facial Wrinkle Scale and Responder rate at Day 30 by patient global assessment of change in appearance. Started Jul 2006; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2005-004416-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004416-78.